Acrivon Presents AP3 Platform at AACR D3 Conference
Acrivon showcases its AP3 platform's capabilities in drug discovery.
Acrivon Therapeutics, Inc. will present its AP3 platform at the upcoming American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference, scheduled for July 21-24, 2026, in Boston. The company aims to demonstrate how its innovative technology can simplify drug discovery and development through pathway-based approaches.
The presentations will focus on ACR-2316, a novel WEE1/PKMYT1 inhibitor designed using the AP3 platform. Early clinical data has indicated promising results, including partial responses in several tumor types predicted by the AP3 platform. This suggests that Acrivon’s data-driven approach may lead to effective treatments for cancers previously unresponsive to similar therapies.
Acrivon's AP3 platform employs advanced phosphoproteomics to identify and advance drug candidates by analyzing drug-regulated pathway activity within cells. The platform's capabilities allow for the detection of resistance mechanisms, which is crucial for developing effective cancer therapies. The company will highlight how ACR-2316 activates critical pathways that contribute to tumor cell death.
Dr. Kristina Masson, co-founder and EVP of Acrivon, stated, “We are excited to present at AACR D3 and to highlight the actionable power of our AP3 platform.” This highlights the platform's potential to transform drug design by focusing on biological pathways rather than traditional target-centric methods.
The oral presentation will feature Dr. Lei Shi discussing the next-generation precision medicine capabilities of the AP3 platform, while a poster will detail the discovery process of ACR-2316. These sessions aim to illustrate the advantages of using AP3 for identifying promising drug candidates that can lead to better clinical outcomes.
As Acrivon continues to advance ACR-2316 into further clinical phases, the company is also developing additional compounds using the AP3 platform. This technology positions Acrivon at the forefront of precision medicine in oncology, potentially leading to more effective treatments for a variety of cancers.
This announcement is based on information provided by Acrivon in a press release distributed via GlobeNewswire.
This is an independent summary of a press release originally distributed via GlobeNewswire. GAX Online was not paid for this coverage.
Have news to announce?
Get your launch, funding round, or partnership covered on GAX Online, in front of tech buyers and the AI answer engines that cite us.
Submit your press release →